Research ExplorerPublicationsTranscatheter Aortic Valve Replacement in Pure Native Aortic...

Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation

Standard

Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. / Yoon, Sung-Han; Schmidt, Tobias; Bleiziffer, Sabine; Schofer, Niklas; Fiorina, Claudia; Munoz-Garcia, Antonio J; Yzeiraj, Ermela; Amat-Santos, Ignacio J; Tchetche, Didier; Jung, Christian; Fujita, Buntaro; Mangieri, Antonio; Deutsch, Marcus-Andre; Ubben, Timm; Deuschl, Florian; Kuwata, Shingo; De Biase, Chiara; Williams, Timothy; Dhoble, Abhijeet; Kim, Won-Keun; Ferrari, Enrico; Barbanti, Marco; Vollema, E Mara; Miceli, Antonio; Giannini, Cristina; Attizzani, Guiherme F; Kong, William K F; Gutierrez-Ibanes, Enrique; Jimenez Diaz, Victor Alfonso; Wijeysundera, Harindra C; Kaneko, Hidehiro; Chakravarty, Tarun; Makar, Moody; Sievert, Horst; Hengstenberg, Christian; Prendergast, Bernard D; Vincent, Flavien; Abdel-Wahab, Mohamed; Nombela-Franco, Luis; Silaschi, Miriam; Tarantini, Giuseppe; Butter, Christian; Ensminger, Stephan M; Hildick-Smith, David; Petronio, Anna Sonia; Yin, Wei-Hsian; De Marco, Federico; Testa, Luca; Van Mieghem, Nicolas M; Whisenant, Brian K; Kuck, Karl-Heinz; Colombo, Antonio; Kar, Saibal; Moris, Cesar; Delgado, Victoria; Maisano, Francesco; Nietlispach, Fabian; Mack, Michael J; Schofer, Joachim; Schaefer, Ulrich; Bax, Jeroen J; Frerker, Christian; Latib, Azeem; Makkar, Raj R.

In: J AM COLL CARDIOL, Vol. 70, No. 22, 05.12.2017, p. 2752-2763.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Yoon, S-H, Schmidt, T, Bleiziffer, S, Schofer, N, Fiorina, C, Munoz-Garcia, AJ, Yzeiraj, E, Amat-Santos, IJ, Tchetche, D, Jung, C, Fujita, B, Mangieri, A, Deutsch, M-A, Ubben, T, Deuschl, F, Kuwata, S, De Biase, C, Williams, T, Dhoble, A, Kim, W-K, Ferrari, E, Barbanti, M, Vollema, EM, Miceli, A, Giannini, C, Attizzani, GF, Kong, WKF, Gutierrez-Ibanes, E, Jimenez Diaz, VA, Wijeysundera, HC, Kaneko, H, Chakravarty, T, Makar, M, Sievert, H, Hengstenberg, C, Prendergast, BD, Vincent, F, Abdel-Wahab, M, Nombela-Franco, L, Silaschi, M, Tarantini, G, Butter, C, Ensminger, SM, Hildick-Smith, D, Petronio, AS, Yin, W-H, De Marco, F, Testa, L, Van Mieghem, NM, Whisenant, BK, Kuck, K-H, Colombo, A, Kar, S, Moris, C, Delgado, V, Maisano, F, Nietlispach, F, Mack, MJ, Schofer, J, Schaefer, U, Bax, JJ, Frerker, C, Latib, A & Makkar, RR 2017, 'Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation', J AM COLL CARDIOL, vol. 70, no. 22, pp. 2752-2763. https://doi.org/10.1016/j.jacc.2017.10.006

APA

Yoon, S-H., Schmidt, T., Bleiziffer, S., Schofer, N., Fiorina, C., Munoz-Garcia, A. J., Yzeiraj, E., Amat-Santos, I. J., Tchetche, D., Jung, C., Fujita, B., Mangieri, A., Deutsch, M-A., Ubben, T., Deuschl, F., Kuwata, S., De Biase, C., Williams, T., Dhoble, A., ... Makkar, R. R. (2017). Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. J AM COLL CARDIOL, 70(22), 2752-2763. https://doi.org/10.1016/j.jacc.2017.10.006

Vancouver

Yoon S-H, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ et al. Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. J AM COLL CARDIOL. 2017 Dec 5;70(22):2752-2763. https://doi.org/10.1016/j.jacc.2017.10.006

Bibtex

@article{f01cab80c84540889977379cfb375aa8,
title = "Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation",
abstract = "BACKGROUND: Limited data exist about safety and efficacy of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation (AR).OBJECTIVES: This study sought to compare the outcomes of TAVR with early- and new-generation devices in symptomatic patients with pure native AR.METHODS: From the pure native AR TAVR multicenter registry, procedural and clinical outcomes were assessed according to VARC-2 criteria and compared between early- and new-generation devices.RESULTS: A total of 331 patients with a mean STS score of 6.7 ± 6.7 underwent TAVR. The early- and new-generation devices were used in 119 patients (36.0%) and 212 patients (64.0%), respectively. STS score tended to be lower in the new-generation device group (6.2 ± 6.7 vs. 7.6 ± 6.7; p = 0.08), but transfemoral access was more frequently used in the early-generation device group (87.4% vs. 60.8%; p < 0.001). Compared with the early-generation devices, the new-generation devices were associated with a significantly higher device success rate (81.1% vs. 61.3%; p < 0.001) due to lower rates of second valve implantation (12.7% vs. 24.4%; p = 0.007) and post-procedural AR ≥ moderate (4.2% vs. 18.8%; p < 0.001). There were no significant differences in major 30-day endpoints between the 2 groups. The cumulative rates of all-cause and cardiovascular death at 1-year follow-up were 24.1% and 15.6%, respectively. The 1-year all-cause mortality rate was significantly higher in the patients with post-procedural AR ≥ moderate compared with those with post-procedural AR ≤ mild (46.1% vs. 21.8%; log-rank p = 0.001). On multivariable analysis, post-procedural AR ≥ moderate was independently associated with 1-year all-cause mortality (hazard ratio: 2.85; 95% confidence interval: 1.52 to 5.35; p = 0.001).CONCLUSIONS: Compared with the early-generation devices, TAVR using the new-generation devices was associated with improved procedural outcomes in treating patients with pure native AR. In patients with pure native AR, significant post-procedural AR was independently associated with increased mortality.",
keywords = "Aged, Aged, 80 and over, Aortic Valve/surgery, Aortic Valve Insufficiency/diagnosis, Catheterization, Peripheral/methods, Female, Femoral Artery/surgery, Heart Valve Prosthesis/adverse effects, Humans, International Cooperation, Male, Mortality, Outcome and Process Assessment, Health Care, Postoperative Complications/diagnosis, Prosthesis Design/trends, Quality Improvement, Registries/statistics & numerical data, Risk Assessment, Severity of Illness Index, Transcatheter Aortic Valve Replacement/adverse effects",
author = "Sung-Han Yoon and Tobias Schmidt and Sabine Bleiziffer and Niklas Schofer and Claudia Fiorina and Munoz-Garcia, {Antonio J} and Ermela Yzeiraj and Amat-Santos, {Ignacio J} and Didier Tchetche and Christian Jung and Buntaro Fujita and Antonio Mangieri and Marcus-Andre Deutsch and Timm Ubben and Florian Deuschl and Shingo Kuwata and {De Biase}, Chiara and Timothy Williams and Abhijeet Dhoble and Won-Keun Kim and Enrico Ferrari and Marco Barbanti and Vollema, {E Mara} and Antonio Miceli and Cristina Giannini and Attizzani, {Guiherme F} and Kong, {William K F} and Enrique Gutierrez-Ibanes and {Jimenez Diaz}, {Victor Alfonso} and Wijeysundera, {Harindra C} and Hidehiro Kaneko and Tarun Chakravarty and Moody Makar and Horst Sievert and Christian Hengstenberg and Prendergast, {Bernard D} and Flavien Vincent and Mohamed Abdel-Wahab and Luis Nombela-Franco and Miriam Silaschi and Giuseppe Tarantini and Christian Butter and Ensminger, {Stephan M} and David Hildick-Smith and Petronio, {Anna Sonia} and Wei-Hsian Yin and {De Marco}, Federico and Luca Testa and {Van Mieghem}, {Nicolas M} and Whisenant, {Brian K} and Karl-Heinz Kuck and Antonio Colombo and Saibal Kar and Cesar Moris and Victoria Delgado and Francesco Maisano and Fabian Nietlispach and Mack, {Michael J} and Joachim Schofer and Ulrich Schaefer and Bax, {Jeroen J} and Christian Frerker and Azeem Latib and Makkar, {Raj R}",
note = "Copyright {\textcopyright} 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = dec,
day = "5",
doi = "10.1016/j.jacc.2017.10.006",
language = "English",
volume = "70",
pages = "2752--2763",
journal = "J AM COLL CARDIOL",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "22",

}

RIS

TY - JOUR

T1 - Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation

AU - Yoon, Sung-Han

AU - Schmidt, Tobias

AU - Bleiziffer, Sabine

AU - Schofer, Niklas

AU - Fiorina, Claudia

AU - Munoz-Garcia, Antonio J

AU - Yzeiraj, Ermela

AU - Amat-Santos, Ignacio J

AU - Tchetche, Didier

AU - Jung, Christian

AU - Fujita, Buntaro

AU - Mangieri, Antonio

AU - Deutsch, Marcus-Andre

AU - Ubben, Timm

AU - Deuschl, Florian

AU - Kuwata, Shingo

AU - De Biase, Chiara

AU - Williams, Timothy

AU - Dhoble, Abhijeet

AU - Kim, Won-Keun

AU - Ferrari, Enrico

AU - Barbanti, Marco

AU - Vollema, E Mara

AU - Miceli, Antonio

AU - Giannini, Cristina

AU - Attizzani, Guiherme F

AU - Kong, William K F

AU - Gutierrez-Ibanes, Enrique

AU - Jimenez Diaz, Victor Alfonso

AU - Wijeysundera, Harindra C

AU - Kaneko, Hidehiro

AU - Chakravarty, Tarun

AU - Makar, Moody

AU - Sievert, Horst

AU - Hengstenberg, Christian

AU - Prendergast, Bernard D

AU - Vincent, Flavien

AU - Abdel-Wahab, Mohamed

AU - Nombela-Franco, Luis

AU - Silaschi, Miriam

AU - Tarantini, Giuseppe

AU - Butter, Christian

AU - Ensminger, Stephan M

AU - Hildick-Smith, David

AU - Petronio, Anna Sonia

AU - Yin, Wei-Hsian

AU - De Marco, Federico

AU - Testa, Luca

AU - Van Mieghem, Nicolas M

AU - Whisenant, Brian K

AU - Kuck, Karl-Heinz

AU - Colombo, Antonio

AU - Kar, Saibal

AU - Moris, Cesar

AU - Delgado, Victoria

AU - Maisano, Francesco

AU - Nietlispach, Fabian

AU - Mack, Michael J

AU - Schofer, Joachim

AU - Schaefer, Ulrich

AU - Bax, Jeroen J

AU - Frerker, Christian

AU - Latib, Azeem

AU - Makkar, Raj R

N1 - Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2017/12/5

Y1 - 2017/12/5

N2 - BACKGROUND: Limited data exist about safety and efficacy of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation (AR).OBJECTIVES: This study sought to compare the outcomes of TAVR with early- and new-generation devices in symptomatic patients with pure native AR.METHODS: From the pure native AR TAVR multicenter registry, procedural and clinical outcomes were assessed according to VARC-2 criteria and compared between early- and new-generation devices.RESULTS: A total of 331 patients with a mean STS score of 6.7 ± 6.7 underwent TAVR. The early- and new-generation devices were used in 119 patients (36.0%) and 212 patients (64.0%), respectively. STS score tended to be lower in the new-generation device group (6.2 ± 6.7 vs. 7.6 ± 6.7; p = 0.08), but transfemoral access was more frequently used in the early-generation device group (87.4% vs. 60.8%; p < 0.001). Compared with the early-generation devices, the new-generation devices were associated with a significantly higher device success rate (81.1% vs. 61.3%; p < 0.001) due to lower rates of second valve implantation (12.7% vs. 24.4%; p = 0.007) and post-procedural AR ≥ moderate (4.2% vs. 18.8%; p < 0.001). There were no significant differences in major 30-day endpoints between the 2 groups. The cumulative rates of all-cause and cardiovascular death at 1-year follow-up were 24.1% and 15.6%, respectively. The 1-year all-cause mortality rate was significantly higher in the patients with post-procedural AR ≥ moderate compared with those with post-procedural AR ≤ mild (46.1% vs. 21.8%; log-rank p = 0.001). On multivariable analysis, post-procedural AR ≥ moderate was independently associated with 1-year all-cause mortality (hazard ratio: 2.85; 95% confidence interval: 1.52 to 5.35; p = 0.001).CONCLUSIONS: Compared with the early-generation devices, TAVR using the new-generation devices was associated with improved procedural outcomes in treating patients with pure native AR. In patients with pure native AR, significant post-procedural AR was independently associated with increased mortality.

AB - BACKGROUND: Limited data exist about safety and efficacy of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation (AR).OBJECTIVES: This study sought to compare the outcomes of TAVR with early- and new-generation devices in symptomatic patients with pure native AR.METHODS: From the pure native AR TAVR multicenter registry, procedural and clinical outcomes were assessed according to VARC-2 criteria and compared between early- and new-generation devices.RESULTS: A total of 331 patients with a mean STS score of 6.7 ± 6.7 underwent TAVR. The early- and new-generation devices were used in 119 patients (36.0%) and 212 patients (64.0%), respectively. STS score tended to be lower in the new-generation device group (6.2 ± 6.7 vs. 7.6 ± 6.7; p = 0.08), but transfemoral access was more frequently used in the early-generation device group (87.4% vs. 60.8%; p < 0.001). Compared with the early-generation devices, the new-generation devices were associated with a significantly higher device success rate (81.1% vs. 61.3%; p < 0.001) due to lower rates of second valve implantation (12.7% vs. 24.4%; p = 0.007) and post-procedural AR ≥ moderate (4.2% vs. 18.8%; p < 0.001). There were no significant differences in major 30-day endpoints between the 2 groups. The cumulative rates of all-cause and cardiovascular death at 1-year follow-up were 24.1% and 15.6%, respectively. The 1-year all-cause mortality rate was significantly higher in the patients with post-procedural AR ≥ moderate compared with those with post-procedural AR ≤ mild (46.1% vs. 21.8%; log-rank p = 0.001). On multivariable analysis, post-procedural AR ≥ moderate was independently associated with 1-year all-cause mortality (hazard ratio: 2.85; 95% confidence interval: 1.52 to 5.35; p = 0.001).CONCLUSIONS: Compared with the early-generation devices, TAVR using the new-generation devices was associated with improved procedural outcomes in treating patients with pure native AR. In patients with pure native AR, significant post-procedural AR was independently associated with increased mortality.

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve/surgery

KW - Aortic Valve Insufficiency/diagnosis

KW - Catheterization, Peripheral/methods

KW - Female

KW - Femoral Artery/surgery

KW - Heart Valve Prosthesis/adverse effects

KW - Humans

KW - International Cooperation

KW - Male

KW - Mortality

KW - Outcome and Process Assessment, Health Care

KW - Postoperative Complications/diagnosis

KW - Prosthesis Design/trends

KW - Quality Improvement

KW - Registries/statistics & numerical data

KW - Risk Assessment

KW - Severity of Illness Index

KW - Transcatheter Aortic Valve Replacement/adverse effects

U2 - 10.1016/j.jacc.2017.10.006

DO - 10.1016/j.jacc.2017.10.006

M3 - SCORING: Journal article

C2 - 29191323

VL - 70

SP - 2752

EP - 2763

JO - J AM COLL CARDIOL

JF - J AM COLL CARDIOL

SN - 0735-1097

IS - 22

ER -